Literature DB >> 15234806

Comparative study of influenza virus replication in Vero and MDCK cell lines.

R Youil1, Q Su, T J Toner, C Szymkowiak, W-S Kwan, B Rubin, L Petrukhin, I Kiseleva, A R Shaw, D DiStefano.   

Abstract

The choice of a cell line for the production of influenza vaccines is determined by how well the virus is able to replicate and how easily the cell line can be maintained. Madin-Darby canine kidney (MDCK) cells have long been known to successfully support influenza growth. Vero cells are also another well studied candidate cell line. In this work, we have compared these two cell lines for their ability to propagate type A and type B cold-adapted and wild type influenza viruses. The growth of these viruses has been measured as plaque forming units (via plaque assay) as well as viral particle formation (via a novel quantitative RT-PCR assay) to assess the suitability of these cell lines to support the development of live attenuated influenza vaccines. The novel qRT-PCR assay outlined in this work was demonstrated to be an efficient, sensitive and reproducible method for measuring wild type (wt) and cold-adapted (ca) influenza strains. Replicates of six per sample consistently showed an average variation around +/-10%. In this study we have also found qRT-PCR to be a useful method for differentiating between wt and ca influenza strains based on their differing growth characteristics at varying temperatures. This can subsequently be used to assess reassortants prepared from ca donor strains for the purposes of live viral vaccine development. For type A and B influenza viruses studied in this work, MDCK cells supported a more rapid viral growth (measured in terms of genome copies) compared with Vero cells. For the type A viruses studied here, the genome copies: infectious unit (genome copy, gc:infectious unit, iu) ratio was found to be more favorable for Vero cells compared with MDCK cells. For the type B viruses studied in this work, the gc:iu was equivalent in both cell lines tested. Ultimately, however, the use of any new cell line would need to be approved by regulatory agencies prior to its commercial application.

Entities:  

Mesh:

Year:  2004        PMID: 15234806     DOI: 10.1016/j.jviromet.2004.03.011

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  22 in total

Review 1.  Cell culture-based influenza vaccines: A necessary and indispensable investment for the future.

Authors:  Nagendra R Hegde
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Transocular entry of seasonal influenza-attenuated virus aerosols and the efficacy of n95 respirators, surgical masks, and eye protection in humans.

Authors:  Werner E Bischoff; Tanya Reid; Gregory B Russell; Timothy R Peters
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

3.  Isolation and genetic characterization of new reassortant H3N1 swine influenza virus from pigs in the midwestern United States.

Authors:  Wenjun Ma; Marie Gramer; Kurt Rossow; Kyoung-Jin Yoon
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

Review 4.  Advances in novel influenza vaccines: a patent review.

Authors:  Jae-Min Song
Journal:  J Microbiol       Date:  2016-05-27       Impact factor: 3.422

5.  Viral concentration determination through plaque assays: using traditional and novel overlay systems.

Authors:  Alan Baer; Kylene Kehn-Hall
Journal:  J Vis Exp       Date:  2014-11-04       Impact factor: 1.355

6.  Cell culture-derived flu vaccine: Present and future.

Authors:  Alberto Pérez Rubio; Jose María Eiros
Journal:  Hum Vaccin Immunother       Date:  2018-06-28       Impact factor: 3.452

Review 7.  Developments of subunit and VLP vaccines against influenza A virus.

Authors:  Ma-ping Deng; Zhi-hong Hu; Hua-lin Wang; Fei Deng
Journal:  Virol Sin       Date:  2012-06-09       Impact factor: 4.327

8.  Adenovirus-mediated artificial MicroRNAs targeting matrix or nucleoprotein genes protect mice against lethal influenza virus challenge.

Authors:  H Zhang; X Tang; C Zhu; Y Song; J Yin; J Xu; H C J Ertl; D Zhou
Journal:  Gene Ther       Date:  2015-04-23       Impact factor: 5.250

9.  Mutational analysis of the binding pockets of the diketo acid inhibitor L-742,001 in the influenza virus PA endonuclease.

Authors:  Annelies Stevaert; Roberto Dallocchio; Alessandro Dessì; Nicolino Pala; Dominga Rogolino; Mario Sechi; Lieve Naesens
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

10.  Conversion of MDCK cell line to suspension culture by transfecting with human siat7e gene and its application for influenza virus production.

Authors:  Chia Chu; Vladimir Lugovtsev; Hana Golding; Michael Betenbaugh; Joseph Shiloach
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.